Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

α4β2* Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease

View ORCID ProfileRoger L. Albin, Martijn L.T.M. Müller, Nicolaas I. Bohnen, Cathie Spino, Martin Sarter, Robert A. Koeppe, Ashley Szpara, Cindy Lustig, William T. Dauer
doi: https://doi.org/10.1101/2020.10.11.20210914
Roger L. Albin
1Neurology Service & GRECC, VAAAAHS GRECC, Ann Arbor, MI, 48105, USA
2Dept. of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA
3University of Michigan Morris K. Udall Parkinson’s Disease Research Center of Excellence, Ann Arbor, MI, 48109, USA
4University of Michigan Parkinson’s Foundation Research Center of Excellence, Ann Arbor, MI, 48109, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Roger L. Albin
  • For correspondence: ralbin@med.umich.edu
Martijn L.T.M. Müller
3University of Michigan Morris K. Udall Parkinson’s Disease Research Center of Excellence, Ann Arbor, MI, 48109, USA
4University of Michigan Parkinson’s Foundation Research Center of Excellence, Ann Arbor, MI, 48109, USA
5Dept. of Radiology, University of Michigan, Ann Arbor, MI, 48109, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolaas I. Bohnen
1Neurology Service & GRECC, VAAAAHS GRECC, Ann Arbor, MI, 48105, USA
2Dept. of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA
3University of Michigan Morris K. Udall Parkinson’s Disease Research Center of Excellence, Ann Arbor, MI, 48109, USA
4University of Michigan Parkinson’s Foundation Research Center of Excellence, Ann Arbor, MI, 48109, USA
5Dept. of Radiology, University of Michigan, Ann Arbor, MI, 48109, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cathie Spino
3University of Michigan Morris K. Udall Parkinson’s Disease Research Center of Excellence, Ann Arbor, MI, 48109, USA
6Dept. of Biostatistics, University of Michigan, Ann Arbor, MI, 48109, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Sarter
3University of Michigan Morris K. Udall Parkinson’s Disease Research Center of Excellence, Ann Arbor, MI, 48109, USA
7Dept. of Psychology, University of Michigan, Ann Arbor, MI, 48109, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert A. Koeppe
5Dept. of Radiology, University of Michigan, Ann Arbor, MI, 48109, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashley Szpara
2Dept. of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA
3University of Michigan Morris K. Udall Parkinson’s Disease Research Center of Excellence, Ann Arbor, MI, 48109, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cindy Lustig
4University of Michigan Parkinson’s Foundation Research Center of Excellence, Ann Arbor, MI, 48109, USA
7Dept. of Psychology, University of Michigan, Ann Arbor, MI, 48109, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William T. Dauer
1Neurology Service & GRECC, VAAAAHS GRECC, Ann Arbor, MI, 48105, USA
2Dept. of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA
3University of Michigan Morris K. Udall Parkinson’s Disease Research Center of Excellence, Ann Arbor, MI, 48109, USA
8Dept. of Neurology, University of Texas Southwestern, Dallas, TX, 75390, USA
9Dept. of Neuroscience, University of Texas Southwestern, Dallas, TX, 75390, USA
10Peter J. O’Donnell Brain Institute, University of Texas Southwestern, Dallas, TX, 75390, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Objective Attentional function deficits secondary to degeneration of brain cholinergic systems are significant contributors to gait-balance deficits in Parkinson disease (PD). To assess whether α4β2* nicotinic acetylcholine receptor (nAChR) stimulation improves attention and gait-balance function, we performed a target engagement study of the α4β2* nAChR partial agonist varenicline.

Methods Non-demented PD participants with cholinergic deficits were identified with [18F]fluoroethoxybenzamicol positron emission tomography (PET). α4β2* nAChR occupancy after subacute oral varenicline treatment was measured with [18F]flubatine PET. With a dose selected from the receptor occupancy experiment, varenicline effects on gait, balance, and cognition were assessed in a double-masked placebo-controlled crossover study. Primary endpoints were normal pace gait speed and a measure of postural stability.

Results Varenicline, 0.25 mg per day, 0.25 mg b.i.d., 0.5 mg b.i.d., and 1.0 mg b.i.d., produced 60% - 70% receptor occupancy, with 0.5 mg po b.i.d chosen for the crossover study. Thirty-three (of thirty-four) participants, completed the crossover study with excellent tolerability. Varenicline had no impact on the postural stability measure and resulted in slower normal pace gait speed. Varenicline reduced distraction effects under dual task gait conditions and improved performance on a sustained attention test. In 28 participants in whom treatment compliance was confirmed by plasma varenicline measurements, we obtained identical conclusions.

Interpretation Varenicline occupied a significant fraction of α4β2* nicotinic acetylcholine receptors, was tolerated well, enhanced attentional function, and improved dual task gait performance. α4β2* nicotinic agonists may be useful in mitigating gait and balance disorders in PD.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04403399; NCT02933372

Funding Statement

Supported by: NIH-NINDS, Michael J. Fox Foundation, and the Parkinson's Foundation

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

University of Michigan IRBMED.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data is available on request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 14, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
α4β2* Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
α4β2* Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease
Roger L. Albin, Martijn L.T.M. Müller, Nicolaas I. Bohnen, Cathie Spino, Martin Sarter, Robert A. Koeppe, Ashley Szpara, Cindy Lustig, William T. Dauer
medRxiv 2020.10.11.20210914; doi: https://doi.org/10.1101/2020.10.11.20210914
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
α4β2* Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease
Roger L. Albin, Martijn L.T.M. Müller, Nicolaas I. Bohnen, Cathie Spino, Martin Sarter, Robert A. Koeppe, Ashley Szpara, Cindy Lustig, William T. Dauer
medRxiv 2020.10.11.20210914; doi: https://doi.org/10.1101/2020.10.11.20210914

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (134)
  • Cardiovascular Medicine (1747)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (653)
  • Epidemiology (10779)
  • Forensic Medicine (8)
  • Gastroenterology (583)
  • Genetic and Genomic Medicine (2933)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1918)
  • Health Policy (833)
  • Health Systems and Quality Improvement (743)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12496)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (321)
  • Neurology (2780)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (553)
  • Occupational and Environmental Health (597)
  • Oncology (1454)
  • Ophthalmology (440)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (379)
  • Pediatrics (864)
  • Pharmacology and Therapeutics (362)
  • Primary Care Research (333)
  • Psychiatry and Clinical Psychology (2630)
  • Public and Global Health (5338)
  • Radiology and Imaging (1002)
  • Rehabilitation Medicine and Physical Therapy (594)
  • Respiratory Medicine (722)
  • Rheumatology (329)
  • Sexual and Reproductive Health (288)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)